FDA Approved: XOLAIR — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for XOLAIR (omalizumab) submitted by Genentech, resulting in a label change/indication update for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Spontaneous Urticaria

Drugs mentioned

• Xolair (omalizumab)

Snippet

SUPPL AP for XOLAIR (OMALIZUMAB)